Search
forLearn
5 / 801 resultslearn AminoMar™
learn Climbazol
learn procapil
learn amodimethicone
Research
5 / 1000+ results
research Efficient and regulable extraction of keratin from yak hair using imidazolium-based ionic liquids
A new method using imidazole-based liquids efficiently extracts keratin from yak hair.
research Proportional Prevalence of Bovine Parasitic Diseases at Mymensingh District of Bangladesh
Cattle in Mymensingh, Bangladesh, face high parasitic disease rates, needing better deworming and management.
research QUEIMADURAS, MEDICINA LEGAL E SINAL DE MONTALTI
research ENRIQUECIMENTO AMBIENTAL ASSOCIADO A PROMOÇÃO DO BEM ESTAR PARA CAMUNDONGOS MANTIDOS EM BIOTÉRIOS
research ALTERAÇÕES MORFOLÓGICAS DA DOENÇA DE PARKINSON UTILIZANDO A RESSONÂNCIA MAGNÉTICA NUCLEAR
Community Join
5 / 1000+ resultscommunity Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community I have heard that Amplifica - Scube3 initiate a human study for AGA, but I cannot find any information about it from clinictrial.gov. Amplifica did not state it is a phase 1 clinic trial or not, it says it is "The initiation of our first-in-human clinical study"
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
community Clascoterone - clearnet vendor
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
community Why there are no updates from Amplifica about SCUBE3 & AMP-303?
Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.
community SCUBE 3 (the last hair bender)
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.